12 Major Risk Factors For Cognitive Decline

Dementia is one of the hardest conditions to watch someone go through.

It affects around 50 million people globally, and that number is only skyrocketing as the years go by.

Some projections indicate that it may triple by 2050.

Why the jump?

It seems that there are 12 major risk factors associated with dementia.

Nine of these have been known for a while:

Lack of early education, mid-life hearing loss, hypertension and obesity, smoking, depression, excessive isolation, physical inactivity, and diabetes at 65 or older.

However, a report presented at the 2020 Alzheimer’s Association International Conference shows that there are three more factors that should be added to the list:

Excessive alcohol intake, air pollution, and head injury.

We all want to age well with minimal diseases, so to prevent dementia, being mindful of these 12 factors is crucial.

Although there are some factors on that list that are outside anyone’s control, there are more things we can do than you might think.

In fact, one of the presenters and medical professional, Dr. Lon Schneider, lays out at an action plan for individuals and policymakers with the goal of reducing dementia cases:

• Aim to maintain systolic blood pressure of 130 mm Hg or less from the age of 40.
• Encourage use of hearing aids for hearing loss and reduce hearing loss by protecting ears from high noise levels.
• Reduce exposure to air pollution and second-hand tobacco smoke.
• Prevent head injury (particularly by targeting high-risk occupations).
• Limit alcohol intake to no more than 21 units per week (one unit of alcohol equals 10 ml or 8 g pure alcohol).
• Stop smoking and support others to stop smoking.
• Provide all children with primary and secondary education.
• Lead an active life into mid-life and possibly later life.
• Reduce obesity and the linked condition of diabetes.

Even though dementia cases at a global level are rising, there’s evidence that countries such as England and France that adopt these positive lifestyle changes are seeing a significant drop in dementia.

5 1 vote
Article Rating
Notify of
Inline Feedbacks
View all comments
Would love your thoughts, please comment.x

Mito Male Scientific References

1. Cavallini, G., Caracciolo, S., Vitali, G., Modenini, F., & Biagiotti, G. (2004). Carnitine versus androgen administration in the treatment of sexual dysfunction, depressed mood, and fatigue associated with male aging. Urology, 63(4), 641-646. doi:10.1016/j.urology.2003.11.009

2. Malaguarnera, M., Cammalleri, L., Gargante, M. P., Vacante, M., Colonna, V., & Motta, M. (2007). L-Carnitine treatment reduces severity of physical and mental fatigue and increases cognitive functions in centenarians: A randomized and controlled clinical trial. The American Journal of Clinical Nutrition, 86(6), 1738-1744. doi:10.1093/ajcn/86.5.1738

3. Karlic, H., & Lohninger, A. (2004). Supplementation of l-carnitine in athletes: Does it make sense? Nutrition, 20(7-8), 709-715. doi:10.1016/j.nut.2004.04.003

4. Samimi, M., Jamilian, M., Ebrahimi, F. A., Rahimi, M., Tajbakhsh, B., & Asemi, Z. (2016). Oral carnitine supplementation reduces body weight and insulin resistance in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial. Clinical Endocrinology,84(6), 851-857. doi:10.1111/cen.13003

5. Sahlin, K. (2011). Boosting fat burning with carnitine: An old friend comes out from the shadow. The Journal of Physiology, 589(7), 1509-1510. doi:10.1113/jphysiol.2011.205815

6. Soczynska, J. K., Kennedy, S. H., Chow, C. S., Woldeyohannes, H. O., Konarski, J. Z., & Mcintyre, R. S. (2008). Acetyl-L-carnitine and α-lipoic acid: Possible neurotherapeutic agents for mood disorders? Expert Opinion on Investigational Drugs, 17(6), 827-843. doi:10.1517/13543784.17.6.827

7. Miyagawa, T., Kawamura, H., Obuchi, M., Ikesaki, A., Ozaki, A., Tokunaga, K., . . . Honda, M. (2013). Effects of Oral L-Carnitine Administration in Narcolepsy Patients: A Randomized, Double-Blind, Cross-Over and Placebo-Controlled Trial. PLoS ONE,8(1). doi:10.1371/journal.pone.0053707

8. Cristofano, A., Sapere, N., Marca, G. L., Angiolillo, A., Vitale, M., Corbi, G., . . . Costanzo, A. D. (2016). Serum Levels of Acyl-Carnitines along the Continuum from Normal to Alzheimers Dementia. Plos One, 11(5). doi:10.1371/journal.pone.0155694

. Fillit, H., & Hill, J. (2004). The Economic Benefits of Acetylcholinesterase Inhibitors for Patients with Alzheimer Disease and Associated Dementias. Alzheimer Disease & Associated Disorders,18. doi:10.1097/01.wad.0000127492.65032.d3

10. Miyata, M., Yoshihisa, A., Yamauchi, H., Owada, T., Sato, T., Suzuki, S., . . . Takeishi, Y. (2014). Impact of sleep-disordered breathing on myocardial damage and metabolism in patients with chronic heart failure. Heart and Vessels, 30(3), 318-324. doi:10.1007/s00380-014-0479-6

11. Lango, R. (2001). Influence of ?-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovascular Research, 51(1), 21-29. doi:10.1016/s0008-6363(01)00313-3

12. Vescovo, G., Ravara, B., Gobbo, V., Sandri, M., Angelini, A., Barbera, M. D., . . . Libera, L. D. (2002). L-Carnitine: A potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure. American Journal of Physiology-Cell Physiology, 283(3). doi:10.1152/ajpcell.00046.2002

13. Shadboorestan, A., Shokrzadeh, M., Ahangar, N., Abdollahi, M., Omidi, M., & Payam, S. S. (2013). The chemoprotective effects of l-carnitine against genotoxicity induced by diazinon in rat blood lymphocyte. Toxicology and Industrial Health,31(12), 1334-1340. doi:10.1177/0748233713491811

14. Chowanadisai, W., Bauerly, K. A., Tchaparian, E., Wong, A., Cortopassi, G. A., & Rucker, R. B. (2009). Pyrroloquinoline Quinone Stimulates Mitochondrial Biogenesis through cAMP Response Element-binding Protein Phosphorylation and Increased PGC-1α Expression. Journal of Biological Chemistry,285(1), 142-152. doi:10.1074/jbc.m109.030130

15. Chowanadisai, W., Bauerly, K. A., Tchaparian, E., Wong, A., Cortopassi, G. A., & Rucker, R. B. (2009). Pyrroloquinoline Quinone Stimulates Mitochondrial Biogenesis through cAMP Response Element-binding Protein Phosphorylation and Increased PGC-1α Expression. Journal of Biological Chemistry, 285(1), 142-152. doi:10.1074/jbc.m109.030130

16. Stites TE, Mitchell AE, Rucker RB. Physiological importance of quinoenzymes and the O-quinone family of cofactors. J Nutr. 2000 Apr;130(4):719-27
17. Steinberg, F., Stites, T. E., Anderson, P., Storms, D., Chan, I., Eghbali, S., & Rucker, R. (2003). Pyrroloquinoline Quinone Improves Growth and Reproductive Performance in Mice Fed Chemically Defined Diets. Experimental Biology and Medicine, 228(2), 160-166. doi:10.1177/153537020322800205

18. Biswas, T. K., Pandit, S., Mondal, S., Biswas, S. K., Jana, U., Ghosh, T., . . . Auddy, B. (2010). Clinical evaluation of spermatogenic activity of processed Shilajit in oligospermia. Andrologia,42(1), 48-56. doi:10.1111/j.1439-0272.2009.00956.x

19. Surapaneni, D. K., Adapa, S. R., Preeti, K., Teja, G. R., Veeraragavan, M., & Krishnamurthy, S. (2012). Shilajit attenuates behavioral symptoms of chronic fatigue syndrome by modulating the hypothalamic–pituitary–adrenal axis and mitochondrial bioenergetics in rats. Journal of Ethnopharmacology, 143(1), 91-99. doi:10.1016/j.jep.2012.06.002

20. Chang, C. S., Choi, J. B., Kim, H. J., & Park, S. B. (2011). Correlation Between Serum Testosterone Level and Concentrations of Copper and Zinc in Hair Tissue. Biological Trace Element Research,144(1-3), 264-271. doi:10.1007/s12011-011-9085-y

21. Plasma Steroid-Binding Proteins in Tumour Diseases. (1984). Molecular Aspects of Medicine, 371-380. doi:10.1016/b978-0-08-033239-0.50032-6